ATE423223T1 - Herz-kreislauf-erkrankung vorhersagende einzelnukleotid-polymorphismen - Google Patents

Herz-kreislauf-erkrankung vorhersagende einzelnukleotid-polymorphismen

Info

Publication number
ATE423223T1
ATE423223T1 AT02800131T AT02800131T ATE423223T1 AT E423223 T1 ATE423223 T1 AT E423223T1 AT 02800131 T AT02800131 T AT 02800131T AT 02800131 T AT02800131 T AT 02800131T AT E423223 T1 ATE423223 T1 AT E423223T1
Authority
AT
Austria
Prior art keywords
atpase
seq
cardiovascular disease
single nucleotide
nucleotide polymorphisms
Prior art date
Application number
AT02800131T
Other languages
English (en)
Inventor
Udo Stropp
Stephan Schwers
Elke Reifenberger
Harald Kallabis
Original Assignee
Siemens Healthcare Diagnostics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siemens Healthcare Diagnostics filed Critical Siemens Healthcare Diagnostics
Application granted granted Critical
Publication of ATE423223T1 publication Critical patent/ATE423223T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/03—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; catalysing transmembrane movement of substances (3.6.3)
    • C12Y306/03009—Na+/K+-exchanging ATPase (3.6.3.9)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT02800131T 2001-10-01 2002-09-27 Herz-kreislauf-erkrankung vorhersagende einzelnukleotid-polymorphismen ATE423223T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01122689A EP1298220A1 (de) 2001-10-01 2001-10-01 Einzelnukleotidpolymorphismen zum vorhersagen kardiovasculären Krankheiten

Publications (1)

Publication Number Publication Date
ATE423223T1 true ATE423223T1 (de) 2009-03-15

Family

ID=8178686

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02800131T ATE423223T1 (de) 2001-10-01 2002-09-27 Herz-kreislauf-erkrankung vorhersagende einzelnukleotid-polymorphismen

Country Status (6)

Country Link
US (2) US20070202506A1 (de)
EP (2) EP1298220A1 (de)
AT (1) ATE423223T1 (de)
AU (1) AU2002333885A1 (de)
DE (1) DE60231222D1 (de)
WO (1) WO2003029486A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386658B1 (de) * 2003-11-26 2014-01-08 Celera Corporation Mit Herzkreislauf-Störungen und Medikamentenansprache assoziierte genetische Polymorphien, Detektionsverfahren und Verwendungen davon
CA2573945A1 (en) * 2004-07-16 2006-01-26 Bayer Healthcare Ag Single nucleotide polymorphisms as prognostic tool to diagnose adverse drug reactions (adr) and drug efficacy
WO2006119905A1 (en) * 2005-05-11 2006-11-16 Sanofi-Aventis Use of a gip promoter polymorphism
US7732139B2 (en) 2005-05-18 2010-06-08 Samsung Electronics Co., Ltd. Multiple SNP for diagnosing cardiovascular disease, microarray and kit comprising the same, and method of diagnosing cardiovascular disease using the same
KR100754398B1 (ko) 2005-05-18 2007-08-31 삼성전자주식회사 심혈관 질환 진단용 다중 ｓｎｐ, 그를 포함하는마이크로어레이 및 키트 및 그를 이용한 심혈관 질환 진단방법
KR100851971B1 (ko) 2005-05-21 2008-08-12 삼성전자주식회사 심근 경색에 관련된 유전자 다형성 및 그의 용도
US8073549B2 (en) * 2006-02-28 2011-12-06 University Of South Florida Method of electrogenically controlling pump molecules
WO2007100872A2 (en) * 2006-02-28 2007-09-07 University Of South Florida Electrogenic pump molecule control
CN109266673A (zh) * 2018-09-28 2019-01-25 成都理工大学 一种大肠杆菌表达载体pBMcopA及其应用
CN111363711B (zh) * 2020-03-13 2022-02-11 南京工业大学 一种利用重组谷氨酸棒杆菌吸附固定化发酵生产赖氨酸的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030204075A9 (en) * 1999-08-09 2003-10-30 The Snp Consortium Identification and mapping of single nucleotide polymorphisms in the human genome
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof

Also Published As

Publication number Publication date
EP1298220A1 (de) 2003-04-02
US20070202506A1 (en) 2007-08-30
DE60231222D1 (de) 2009-04-02
AU2002333885A1 (en) 2003-04-14
US20100190169A1 (en) 2010-07-29
EP1434884A2 (de) 2004-07-07
WO2003029486A3 (en) 2003-12-11
WO2003029486A2 (en) 2003-04-10
EP1434884B1 (de) 2009-02-18

Similar Documents

Publication Publication Date Title
Hart et al. Amelogenesis imperfecta phenotype–genotype correlations with two amelogenin gene mutations
Pachebat et al. The 22 kDa component of the protein complex on the surface of Plasmodium falciparum merozoites is derived from a larger precursor, merozoite surface protein 7
AU2002319142B2 (en) New polynucleotides and polypeptides of the erythropoietin gene
JP4723550B2 (ja) 生存運動ニューロン（ｓｍｎ）遺伝子；脊髄筋萎縮
US7041794B2 (en) Polynucleotides and polypeptides of the erythropoietin gene
WO2002072596A1 (en) Steap-related protein
CA2464121C (en) Pregnancy-associated plasma protein-a2 (papp-a2)
ATE423223T1 (de) Herz-kreislauf-erkrankung vorhersagende einzelnukleotid-polymorphismen
DE69829857D1 (de) Hypoxie-regulierte gene
US6025143A (en) Antibodies directed against peptides derived from the SMR1 polypeptide
Glowacki et al. Structure, chromosomal localization, and expression of the gene for mouse ecto-mono (ADP-ribosyl) transferase ART5
DE69911226D1 (de) Prädiktive und therapeutische für nierenerkrankungen gene und proteine
KR20000048838A (ko) 사람의 성장 유전자 및 작은 키 유전자 영역
DE69903278D1 (de) Verfahren zur Diagnose oder zur Prognose von Alzheimer Krankheit: therapeutische Zusammensetzung zur Verhinderung oder zur Behandlung von Alzheimer Krankheit
FR2756845B1 (fr) Sequence nucleotidique codant pour une flavine monooxygenase , proteine correspondante et composition destinee au diagnostic et a la therapie du glaucome
ATE449171T1 (de) Reagentia und verfahren zum nachweis von brustkrankheiten
Fuchs et al. Structure and erythroid cell-restricted expression of a chicken cDNA encoding a novel zinc finger protein of the Cys+ His class
WO2003020911A3 (en) Human schizophrenia gene
WO2003057911A3 (en) Single nucleotide polymorphisms predicting cardiovascular disease and medication efficacy
US20030054446A1 (en) Novel retina-specific human proteins C7orf9, C12orf7, MPP4 and F379
WO1994008037A1 (en) Human homologs of the transducin-like enhancer of split gene and methods based thereon
US6521410B1 (en) Mutant of tissue factor pathway inhibitor, DNA sequence and use for detecting thrombotic disorders
US6001975A (en) Precursor processed to at least one tumor rejection antigen presented by HLA-A2
US20020106664A1 (en) Tapasin-like protein
WO2003059946A3 (en) Genetic polymorphisms predicting cardiovascular disease and medication efficacy

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties